Ergomed Plc

  • Market Cap: N/A
  • Industry: Miscellaneous Commercial Services
  • ISIN: GB00BN7ZCY67
GBP
13.46
0.00 (0.00%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

281.0 k

Shareholding (Dec 2021)

FII

38.86%

Held by 114 FIIs

DII

0

Held by 1 DIIs

Promoter

0.00%

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Miscellaneous Commercial Services

stock-summary
Market cap

GBP 701 Million ()

stock-summary
P/E

44.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.27

stock-summary
Return on Equity

17.69%

stock-summary
Price to Book

7.71

Revenue and Profits:
Net Sales:
(Quarterly Results - )
Net Profit:
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
20.83%
0%
20.83%
6 Months
25.79%
0%
25.79%
1 Year
5.65%
0%
5.65%
2 Years
-11.45%
0%
-11.45%
3 Years
70.38%
0%
70.38%
4 Years
278.09%
0%
278.09%
5 Years
797.33%
0%
797.33%

Ergomed Plc for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
24.70%
EBIT Growth (5y)
58.53%
EBIT to Interest (avg)
13.32
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.27
Sales to Capital Employed (avg)
1.68
Tax Ratio
15.10%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
29.91%
ROE (avg)
20.60%
Valuation key factors
Factor
Value
P/E Ratio
44
Industry P/E
Price to Book Value
7.71
EV to EBIT
34.89
EV to EBITDA
27.17
EV to Capital Employed
10.17
EV to Sales
4.45
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
29.16%
ROE (Latest)
17.69%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
Bearish
No Signal
Bollinger Bands
Mildly Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Mildly Bullish
No Trend
OBV
Bullish
Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Dec 2021stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Non Institution

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 114 Foreign Institutions (38.86%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "alert": "No Quarterly Results declared by Ergomed Plc"
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'22",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2022 is 22.51% vs 37.27% in Dec 2021",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2022 is 18.11% vs 30.93% in Dec 2021",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'22",
        "Dec'21",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "145.30",
          "val2": "118.60",
          "chgp": "22.51%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "25.50",
          "val2": "23.30",
          "chgp": "9.44%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.70",
          "val2": "0.40",
          "chgp": "75.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-1.90",
          "val2": "-5.00",
          "chgp": "62.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "15.00",
          "val2": "12.70",
          "chgp": "18.11%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "135.10%",
          "val2": "154.00%",
          "chgp": "-1.89%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Annual Results Snapshot (Consolidated) - Dec'22stock-summary
Dec'22
Dec'21
Change(%)
Net Sales
145.30
118.60
22.51%
Operating Profit (PBDIT) excl Other Income
25.50
23.30
9.44%
Interest
0.70
0.40
75.00%
Exceptional Items
-1.90
-5.00
62.00%
Consolidate Net Profit
15.00
12.70
18.11%
Operating Profit Margin (Excl OI)
135.10%
154.00%
-1.89%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2022 is 22.51% vs 37.27% in Dec 2021

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2022 is 18.11% vs 30.93% in Dec 2021

stock-summaryCompany CV
About Ergomed Plc stock-summary
stock-summary
Ergomed Plc
Miscellaneous Commercial Services
Ergomed plc is a provider of drug development services to the pharmaceutical industry. The Company operates through two segments: clinical research services (CRS), and drug safety and medical information services (DS&MI). It provides a range of clinical trial planning, management and monitoring services. It is focused on oncology, neurology and immunology, and the development of orphan drugs. It has two businesses: Services Business and Co-Development Business. The Services Business is a clinical research business providing services to the pharmaceutical and biotechnology industry. The Co-Development Business is a portfolio of partnerships with pharmaceutical and biotechnology companies, providing its drug development services in exchange for a carried interest in any revenues attributable to the drug asset, including out licensing milestones, as well as sales of the product. It provides clinical development, trial management and pharmacovigilance services to over 100 clients.
Company Coordinates stock-summary
Company Details
1 Occam Court, Occam Road , GUILDFORD None : GU2 7HJ
stock-summary
Tel: 44 1483 503205
stock-summary
Registrar Details